Recipient hepatectomy technique may affect oncological outcomes of Liver Transplantation for hepatocellular carcinoma.


Journal

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185

Informations de publication

Date de publication:
01 Apr 2024
Historique:
received: 19 07 2023
accepted: 14 03 2024
medline: 29 3 2024
pubmed: 29 3 2024
entrez: 29 3 2024
Statut: aheadofprint

Résumé

To date, caval sparing (CS) and total caval replacement (TCR) for recipient hepatectomy in liver transplantation (LT) have been compared only in terms of surgical morbidity. Nonetheless, CS technique is inherently associated with an increased manipulation of the native liver and later exclusion of the venous outflow, which may increase the risk of intraoperative shedding of tumor cells when LT is performed for hepatocellular carcinoma (HCC). A multicenter, retrospective study was performed to assess the impact of recipient hepatectomy (CS vs. TCR) on the risk of post-transplant HCC recurrence, among 16 European Transplant Centers that used either TCR or CS recipient hepatectomy, as elective protocol technique. Exclusion criteria comprised cases of non-Center-protocol recipient hepatectomy technique, living-donor LT, HCC diagnosis suspected on preoperative imaging but not confirmed at pathological examination of the explanted liver, HCC in close contact with the inferior vena cava and previous liver resection for HCC. In 2420 patients, CS and TCR approaches were used in 1452 (60%) and 968 (40%) cases, respectively. Group adjustment with inverse probability weighting was performed for high volume center, recipient age, alcohol abuse, viral hepatitis, Child-Pugh class C, MELD score, cold ischemia time, clinical HCC stage within Milan criteria, pre-LT downstaging/bridging therapies, pre-LT AFP serum levels, number and size of tumor nodules, microvascular invasion and complete necrosis of all tumor nodules (matched cohort, TCR, n=938; CS, n=935). In a multivariate cause-specific hazard model, CS was associated with a higher risk of HCC recurrence(HR 1.536, p=0.007). TCR recipient hepatectomy, compared to CS approach, may be associated with some protective effect against post-LT tumor recurrence.

Sections du résumé

BACKGROUND BACKGROUND
To date, caval sparing (CS) and total caval replacement (TCR) for recipient hepatectomy in liver transplantation (LT) have been compared only in terms of surgical morbidity. Nonetheless, CS technique is inherently associated with an increased manipulation of the native liver and later exclusion of the venous outflow, which may increase the risk of intraoperative shedding of tumor cells when LT is performed for hepatocellular carcinoma (HCC).
METHODS METHODS
A multicenter, retrospective study was performed to assess the impact of recipient hepatectomy (CS vs. TCR) on the risk of post-transplant HCC recurrence, among 16 European Transplant Centers that used either TCR or CS recipient hepatectomy, as elective protocol technique. Exclusion criteria comprised cases of non-Center-protocol recipient hepatectomy technique, living-donor LT, HCC diagnosis suspected on preoperative imaging but not confirmed at pathological examination of the explanted liver, HCC in close contact with the inferior vena cava and previous liver resection for HCC.
RESULTS RESULTS
In 2420 patients, CS and TCR approaches were used in 1452 (60%) and 968 (40%) cases, respectively. Group adjustment with inverse probability weighting was performed for high volume center, recipient age, alcohol abuse, viral hepatitis, Child-Pugh class C, MELD score, cold ischemia time, clinical HCC stage within Milan criteria, pre-LT downstaging/bridging therapies, pre-LT AFP serum levels, number and size of tumor nodules, microvascular invasion and complete necrosis of all tumor nodules (matched cohort, TCR, n=938; CS, n=935). In a multivariate cause-specific hazard model, CS was associated with a higher risk of HCC recurrence(HR 1.536, p=0.007).
CONCLUSIONS CONCLUSIONS
TCR recipient hepatectomy, compared to CS approach, may be associated with some protective effect against post-LT tumor recurrence.

Identifiants

pubmed: 38551397
doi: 10.1097/LVT.0000000000000373
pii: 01445473-990000000-00356
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024 American Association for the Study of Liver Diseases.

Auteurs

Riccardo Pravisani (R)

Liver-Kidney Transplant Unit, Department of Medicine - University of Udine. Udine, Italy.

Maria De Martino (M)

Division of Medical Statistic, Department of Medicine - University of Udine. Udine, Italy.

Federico Mocchegiani (F)

HPB and Transplantation Unit - Department of Experimental and Clinical Medicine, United Hospital of Ancona- Polytechnic University of Marche, Ancona, Italy.

Fabio Melandro (F)

Division of Hepatic Surgery and Liver Transplantation, University Hospital of Pisa, Pisa, Italy.

Damiano Patrono (D)

General Surgery 2U - Liver Transplant Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino - University of Turin, Torino, Italy.

Andrea Lauterio (A)

Department of Transplantation, Division of General Surgery and Transplantation, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.

Fabrizio Di Francesco (F)

Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, IRCCS-ISMETT, UPMC (University of Pittsburgh Medical Center), Palermo, Italy.

Matteo Ravaioli (M)

General Surgery and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Sant'Orsola-Malpighi Hospital; University of Bologna, Bologna, Italy.

Marco Fabrizio Zambelli (MF)

Department of Organ Failure and Transplantation, ASST Papa Giovanni XXIII, Bergamo, Italy.

Claudio Bosio (C)

USD Trapianti Epatici, AUOI Verona, Verona, Italy.

Daniele Dondossola (D)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Università degli Studi di Milano, Milano, Italy.

Quirino Lai (Q)

General Surgery and Organ Transplantation Unit, AOU Policlinico Umberto I, Sapienza University of Rome, Roma, Italy.

Matteo Zanchetta (M)

Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tubingen, Germany.

Jule Dingfelder (J)

Dept. of General Surgery, Division of Transplantation, Medical University of Vienna, Vienna, Austria.

Luca Toti (L)

Transplant and HPB Unit, Department of Surgery Sciences, University of Rome Tor Vergata, Roma, Italy.

Alessandro Iacomino (A)

UOC Hepato-biliary Surgery and Liver Transplant Centre, AORN Antonio Cardarelli, Napoli, Italy.

Sermed Nicolae (S)

Department of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Davide Ghinolfi (D)

Division of Hepatic Surgery and Liver Transplantation, University Hospital of Pisa, Pisa, Italy.

Renato Romagnoli (R)

General Surgery 2U - Liver Transplant Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino - University of Turin, Torino, Italy.

Luciano De Carlis (L)

Department of Transplantation, Division of General Surgery and Transplantation, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.

Salvatore Gruttadauria (S)

Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, IRCCS-ISMETT, UPMC (University of Pittsburgh Medical Center), Palermo, Italy.
Department of Surgery and Medical and Surgical Specialties, University of Catania, Catania, Italy.

Matteo Cescon (M)

General Surgery and Transplant Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Sant'Orsola-Malpighi Hospital; University of Bologna, Bologna, Italy.

Michele Colledan (M)

Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
Department of Organ Failure and Transplantation, ASST Papa Giovanni XXIII, Bergamo, Italy.

Amedeo Carraro (A)

USD Trapianti Epatici, AUOI Verona, Verona, Italy.

Lucio Caccamo (L)

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.

Marco Vivarelli (M)

HPB and Transplantation Unit - Department of Experimental and Clinical Medicine, United Hospital of Ancona- Polytechnic University of Marche, Ancona, Italy.

Massimo Rossi (M)

General Surgery and Organ Transplantation Unit, AOU Policlinico Umberto I, Sapienza University of Rome, Roma, Italy.

Silvio Nadalin (S)

Department of General, Visceral and Transplant Surgery, University Hospital Tübingen, Tubingen, Germany.

Georg Gyori (G)

Dept. of General Surgery, Division of Transplantation, Medical University of Vienna, Vienna, Austria.

Giuseppe Tisone (G)

Transplant and HPB Unit, Department of Surgery Sciences, University of Rome Tor Vergata, Roma, Italy.

Giovanni Vennarecci (G)

UOC Hepato-biliary Surgery and Liver Transplant Centre, AORN Antonio Cardarelli, Napoli, Italy.

Andreas Rostved (A)

Department of Surgery and Transplantation, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

Paolo De Simone (P)

Department of Surgical, Medical, Biochemical Pathology and Intensive Care, University of Pisa, Pisa, Italy.

Miriam Isola (M)

Division of Medical Statistic, Department of Medicine - University of Udine. Udine, Italy.

Umberto Baccarani (U)

Liver-Kidney Transplant Unit, Department of Medicine - University of Udine. Udine, Italy.

Classifications MeSH